STALEY CAPITAL ADVISERS’s Blueprint Medicines BPMC Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,000	Closed	-$321K	–	182
2021 Q4	$321K	Hold	3,000	–	–	0.02%	149
2021 Q3	$308K	Hold	3,000	–	–	0.02%	149
2021 Q2	$264K	Hold	3,000	–	–	0.01%	157
2021 Q1	$292K	Hold	3,000	–	–	0.02%	152
2020 Q4	$336K	Hold	3,000	–	–	0.02%	139
2020 Q3	$278K	Hold	3,000	–	–	0.02%	137
2020 Q2	$234K	Buy	+3,000	New	+$203K	0.02%	139
2020 Q1	–	Sell	-3,000	Closed	-$240K	–	149
2019 Q4	$240K	Hold	3,000	–	–	0.02%	157
2019 Q3	$220K	Hold	3,000	–	–	0.02%	160
2019 Q2	$283K	Hold	3,000	–	–	0.02%	142
2019 Q1	$240K	Buy	+3,000	New	+$222K	0.02%	146

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

STALEY CAPITAL ADVISERS's BPMC Position: Q1 2022 in Review

STALEY CAPITAL ADVISERS sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 3,000 shares — an estimated $321K sold.

STALEY CAPITAL ADVISERS first reported a position in BPMC in Q1 2019 and held it in 11 quarters. The position peaked at $336K in Q4 2020. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

STALEY CAPITAL ADVISERS reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
STALEY CAPITAL ADVISERS sold 3,000 Blueprint Medicines shares in Q1 2022, an estimated $321K.
STALEY CAPITAL ADVISERS first reported a position in Blueprint Medicines in Q1 2019 and held it in 11 quarters.
STALEY CAPITAL ADVISERS's Blueprint Medicines position peaked at $336K in Q4 2020.
248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q1 2022, filed 12 May 2022.